Table 1.
Summary of the clinical, histological, and immunohistochemical variables analyzed in BCC patients, stratified by treatment-responsive and -nonresponsive groups.
Fig 1.
(a) Peritumoral inflammation surrounding basal cell carcinoma in a MAL-PDT-sensitive BCC (10×). (b) p53 immunostaining in a MAL-PDT responsive BCC: 97% of cells exhibit positive p53 immunostaining (5×). (c) Intense β-catenin immunostaining in a MAL-PDT-sensitive BCC (10×) and (d) enhanced peripheral palisading in a MAL-PDT-resistant BCC (40x). Bar charts depict levels of perilesional inflammatory infiltrate, p53 immunoexpression, and the intensity and distribution of β-catenin immunostaining in BCCs treated with MAL-PDT (responsive and nonresponsive). Scale bar: 200 μm (A and C), 500 μm (B) and 100 μm (D).
Table 2.
Results of the multiple logistic regression model showing variables significantly associated with treatment response: age, BCC subtype, presence of inflammatory infiltrate, and positive p53 immunostaining.
Fig 2.
Expression of p53, β-catenin and ciclin D1 in BCC mice lines.
(A) Expression pattern of p53, β-catenin and ciclin D1 on ASZ and BSZ cells by immunofluorescence. Scale bar: 20um. (B) Protein quantification by Western Blot of (a) p53 and (b) β-catenin. Load control: β-actin. (C) Relative fluorescence of cyclin d1 expression by immunofluorescence. *p< 0.05; ***p< 0.001.
Fig 3.
(a) Cell viability of ASZ and BSZ cells as determined by MTT assay in drug control (0.3 mM MAL), light control (2.25 J/cm2), and PDT (0.3 mM MAL + 0.5 J/cm2 or 0.3 mM MAL + 2.25 J/cm2) conditions. **p <0.01. (b) Photographs of ASZ and BSZ cells following PDT. Scale bar, 200 μm.